PEB.NZX

Pacific Edge Limited

Our view

You need to become a client or login to see Forsyth Barr’s current view.

Recent research View all research

About Pacific Edge Limited

Pacific Edge is a cancer diagnostics company in the early stages of commercialisation of its first product, Cxbladder, after 10 years of research into genetic markers. Cxbladder is a suite of non-invasive urine tests to detect the presence of bladder cancer in patients presenting with haematuria. PEB has two products in the market, Cxbladder Detect and Cxbladder Triage, with an eventual target of four to six Cxbladder products. PEB also has a suite of products in various stages of development for melanoma, colorectal cancer, endometrial cancer and gastric cancer.

Forsyth Barr Analyst

Share price performance

All stock prices and news delayed 20 minutes

02:49 December 13th 2017 NZDT

0.36 0.0%

0.35 Buy

0.36 Sell

Last 0.36

Open 0.37

High 0.37

Low 0.35

Volume 64,540

Turnover $23,088

Most recent trades All trades for the day

Time Price Volume Value
16:59 0.36 13,950 $5,022.00
15:48 0.35 1,181 $413.35
13:39 0.36 10,000 $3,600.00
13:04 0.36 30,000 $10,650.00
12:59 0.36 6,409 $2,307.24

Latest Pacific Edge Limited research

Today's trades

Trade Number Time Price Volume Value
6 16:59 0.36 13,950 $5,022.00
5 15:48 0.35 1,181 $413.35
4 13:39 0.36 10,000 $3,600.00
3 13:04 0.36 30,000 $10,650.00
2 12:59 0.36 6,409 $2,307.24
1 10:00 0.37 3,000 $1,095.00

Latest Pacific Edge Limited news Show more news

If you're new to investing or just have a question please call us: 0800 367 227